

## Study Profile

# National and Sub-national Burden of Infectious Diseases in Iran, 1990 to 2013: The Study Protocol

Atefeh Noori MSc<sup>1,2</sup>, Mostafa Shokoohi MSc<sup>3</sup>, Babak Moazen BSc<sup>1,2</sup>, Ghobad Moradi MD PhD<sup>4</sup>, Shohreh Naderimagham MPH PhD<sup>1,2</sup>, Shayesteh Hajizadeh MPH PhD Candidate<sup>1,5,6</sup>, Alireza Zohouri Zangeneh MSc<sup>1,2</sup>, Mohammad Mehdi Gouya MD<sup>7</sup>, Farshad Farzadfar MD MPH DSc<sup>1,2</sup>

## Abstract

**Background:** To assess the burden of infectious diseases, it is necessary to utilize a systematic approach for data collection and deploying the sophisticated methods to estimate the burden of infectious diseases for health policy making at national level. The present study protocol is aimed to provide a comprehensive explanation of the general structure and method used in the national and sub-national burden of selected infectious diseases study in Iran from 1990 to 2013.

**Methods:** The trend, burden, and geographical inequality pattern of infectious diseases will be estimated through a comprehensive review of published and unpublished data. Different sources of data including health surveys, surveillance data, hospital data surveys, death registry system, census, household expenditure survey, and published manuscripts will be synthesized to calculate the estimates. All indicators will be reported by gender, age, and geographic area. Two different statistical models include "Spatio-Temporal" and "Bayesian multilevel autoregressive" will be applied to overcome the scarcity and misalignment of the obtained data.

**Discussion:** Estimating the prevalence trend and burden of infectious diseases would be helpful to use more cost-effective interventions considering sub-national variations. Additionally, the information obtained from these studies can depict the ability of health system authorities in controlling these types of diseases. Overall, the present applied models can be deployed as a part of inputs in further studies to estimate the burden of diseases, not only in Iran but also all around the Middle East countries.

**Keywords:** Burden of diseases, DALY, infectious diseases, Iran, study profile, YLD, YLL

**Cite this article as:** Noori A, Shokoohi M, Moazen B, Moradi Gh, Naderimagham Sh, Hajizadeh Sh, et al. National and sub-national burden of infectious diseases in Iran, 1990 to 2013: The study protocol. *Arch Iran Med.* 2014; **17**(3): 169 – 175.

## Introduction

Infectious diseases impose a huge load of burden on the health care systems globally.<sup>1-4</sup> This is evidenced by the considerable rates of morbidity, mortality, and related costs associated with these types of disease around the whole world.<sup>5</sup> Drawing on the results of the Global Burden of Disease project (GBD) in 2010,<sup>6</sup> infectious diseases such as diarrhea, lower respiratory infectious diseases, HIV/AIDS, and malaria were ranked among the top ten diseases with the highest amount of burden. Continual possibility of wildlife-to-human transmission, as well as being re-emerging over time and consequently deadly human pandemics are among the other parameters introducing infectious diseases as

one of the most important worldwide health disasters.<sup>7</sup>

Considering the variety of geographical and socio-economic situations in Iran, infectious diseases are known as a major health concern in this country. Drawing on the Joint United Nations Programme on HIV/AIDS (UNAIDS) global report, it was estimated that roughly 71,000 (53,000 – 100,000) individuals were living with HIV to the end of 2012, while this number is still increasing over time.<sup>8</sup> Being located in the vicinity of endemic countries such as Pakistan and Afghanistan might partly justify the considerable prevalence rate of TB, especially in border cities of east and southeastern of Iran.<sup>9</sup> Approximately 3000 cases of Malaria were reported from Iran in 2010, while 95 % of the patients were living in only three provinces.<sup>10</sup> Brucellosis is one of the other major infectious diseases especially among people in rural areas of Iran, which its considerable prevalence might somehow be related to the economic dependency of rural population on livestock and agriculture activities in Iran.<sup>11</sup> Above-mentioned examples demonstrate that infectious diseases should still be considered as major health problems in Iran.

Estimation of the burden of diseases seems to be necessary to take proper decisions toward healthcare cost management, determination of health priorities, definition of the extension of different diseases, and application the effective interventions to mitigate the consequences of infectious diseases in the communities. In addition, conducting the research projects in national and sub-national scales to estimate the burden and trend of infectious diseases might be helpful to provide a unique opportunity for the policymakers to fill the existing information gaps of the health-

**Authors' affiliations:** <sup>1</sup>Non-communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, <sup>2</sup>Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, <sup>3</sup>Regional Knowledge Hub, and WHO Collaborating Centre, Institute For Futures Studies In Health, Kerman University Of Medical Sciences, Kerman, Iran, <sup>4</sup>Kurdistan Research Center for Social Determinants of Health (KRCS DH), Kurdistan University of Medical Sciences, Sanandaj, Iran, <sup>5</sup>Department of Maternal and Child Health, Nursing and Midwifery School, Tehran University of Medical Sciences, Tehran, Iran, <sup>6</sup>Department of Midwifery and Reproductive Health, Nursing and Midwifery School, Shahid Beheshti University of Medical Sciences, Tehran, Iran, <sup>7</sup>Center for Disease Control (CDC), Ministry of Health and Medical Education, Tehran, Iran.

**Corresponding author and reprints:** Farshad Farzadfar MD DSc, Non-Communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Address: No. 4, Nejat Allahi Ave, Enqelab St, Tehran, Iran. Tel/Fax: +98-21-8891-3543; Email: f-farzadfar@tums.ac.ir

Accepted for publication: 30 December 2013

care system, as well as to compare the national results with the regional and global statistics. As a sub-component of the National and Sub-national Burden of Diseases (NASBOD) research project, the present study is advanced to calculate the burden of infectious diseases in Iran in a 23-year period from 1990 to 2013.

## Materials and Methods

In the Burden of Infectious Diseases study (BID), the prevalence, incidence and measures for burden of infectious diseases including Years of Life Lost (YLLs), Years Lived with Disability (YLDs), and Disability Adjusted with Life Years (DALYs) will be estimated. The above-mentioned indicators will be reported by gender, age, and province from 1990 to 2013. Likewise, we will provide the uncertainty levels associated with these estimations.

To make consistency among the entire groups, numerous workshops were held for the team members and researchers based on their educational needs toward burden of diseases and standards of systematic review with a focus on the burden concept. Thereafter, technical team prepared a research proposal for each selected disease. In order to develop a specific and pre-defined study framework, an expert panel was held with the participation of experts consisted of the head of infectious diseases department, Ministry of Health (MOH), infectious diseases specialists, community medicine specialists, public health experts and epidemiologists. The selected diseases were defined according to the list of infectious diseases adopted for the Global Burden of Diseases (GBD) in 2010,<sup>6</sup> as well as numerous experts' points of view. The framework was modified with consideration of the prevalence, incidence, duration and severity, impact of diseases on the people's health, and data availability. Meanwhile, some other diseases including poliomyelitis, rubella, hemorrhagic fevers and brucellosis due to their importance for policy makers or prevalence among Iranian population, these diseases were also added to the current list. However, some other diseases such as dengue fever, varicella, Influenza and hookworm were excluded from the final list due to their low prevalence or not being of the high priority of Iran's ministry of health, or sub-optimal data availability; we reclassified the included diseases into eight categories as shown in the Table 1.

### Ethical consideration

The ethical committee of Tehran University of Medical Sciences declared ethical approval and the permission for the publication of results depends on the funder approval.

### Data collection sources

The investigators will use a systematic and comprehensive approach to provide comprehensive information about the variety of the prevalence and incidence of infectious diseases, at national, provincial, and district levels among Iranian general population. We will obtain data by searching the names of infectious diseases and the related Medical Subject Headings (MeSH) terms and all subheadings in the international (PubMed, ISI the Web of Science, and Scopus), and national databases (IranMedex, Irandoc and SID). In addition, congress abstracts, conference proceedings, theses, and reports published in related databases in Persian language, such as IranMedex, Irandoc and SID, will be assessed. To find the standard search terms the MeSH terms and Entry Terms (the PubMed thesaurus), and Emtree (the EMBASE thesaurus) will be used. Details on our search strategy and search terms

which will be used to obtain the needed data is available in the appendix 1. The Persian keywords for searching in domestic search engines will be equivalent to their English words and all probable combinations will be taken into account. We will also review the reference lists of the included article and relevant review articles.

### Inclusion and exclusion criteria

The entire cross-sectional studies, results of the baseline of cohort studies and national surveys that estimated prevalence of selected diseases will be included. All national, provincial, district, and community studies conducted from January 1990 to December 2013, which reports prevalence or incidence data, will be included in the study. In the BID study, we don't have any language restriction. Results of the case reports and review articles, studies that have not provide a clear confirmation laboratory test for diagnosis of diseases, as well as the studies which have used convenient or non-random sampling will be excluded.

### Study Selection Process

Reviewers will skim the titles. If the title meets inclusion criteria, the article will be evaluated by reviewing the abstract. The abstract review phase is designed to identify studies reporting the prevalence, incidence of diseases and their estimated uncertainty. The abstracts will be reviewed independently by two investigators, and will be excluded if both investigators agree that the article meets one or more of the exclusion criteria. Disagreement between investigators regarding abstract inclusion or exclusion will be resolved through consensus adjudication. In case of missing or vague data, the researchers will send emails to the corresponding authors and ask them to clarify the vague issues. The articles promoted on the basis of abstract review will undergo another independent parallel review to determine if they should be included based on full text review. We will identify additional data sources through personal communications with researchers.

### Quality Assessment

A quality assessment form will be designed to screen all extracted articles in order to be scored. The scoring system will be based on the study characteristic sheet. This sheet will be designed according to the Newcastle Ottawa scale<sup>12</sup> with emphasis on the study design, scope, and level of study, sampling method, sample size, study populations, response rate and measurement method. Afterwards the completing quality assessment form by two researchers, disagreements will be discussed to resolve the existed inconsistency. Technical team will develop a data extraction form in which data will be categorized based on age, sex, scale of the study (National, provincial, district or community), scope of the study (urban, rural), and study year. Other main variables are prevalence, incidence, standard deviation (SD), confidence interval (CI) and/or standard error (SE) of the selected diseases.

### Other Sources

We will use all infectious diseases surveillance data collected by Iranian CDCs, especially the data about tuberculosis, malaria, sexually transmitted diseases and HIV/AIDS, vaccine preventable diseases, and zoonosis diseases surveillance system. In order to have an estimation of the prevalence of specific diseases such as HIV we will also collect data on the size of the specific sub populations of HIV high risk groups including People Who Inject Drugs (PWIDs), Female Sex Workers (FSWs), and Men who

**Table 1.** Selected infectious diseases in Iran

Disease	ICD10 code
<b>Sexually transmitted diseases</b>	
HIV/AIDS	B20
Chancroid	A57
Chlamydia Infections	A56
Gonorrhea	A54
Syphilis	A50
<b>TB</b>	A15
<b>Vaccine preventable diseases</b>	
Measles	B05
Rubella	B06
Tetanus	A33
Dyphtheria	A36
Pertosis	A37
Acute poliomyelitis	A80
<b>Zoonosis</b>	
Rabies	A82
Bruceellosis	A23
Leishmaniasis	B55
Hydatid cysts	B67
Hemorrhagic Fever	A98
<b>Malaria</b>	B50
<b>Meningitis</b>	A87
<b>Encephalitis</b>	A83
<b>Acute upper and lower respiratory infectious diseases</b>	J00 and J20

have Sex with Men (MSMs).

Blood donors' registration system data (the results of both taken and rejected people who volunteered for blood transfusion studies) from Iranian Blood Transfusion Organization (IBTO) as a data sources will be used for our modeling to estimate the general population prevalence and subsequently burden of diseases.

Hospital Data Survey provides inpatient data about the related diseases and morbidity in hospitals in Iran also data of the death registration system of Ministry of Health will be used in order to obtain cause specific mortality records. The prescribed drugs for STIs patients, which acquired by Outpatient Data Survey will be used as an indirect method to estimate the prevalence of these diseases. Census and household expenditure survey are other sources of data, which will be used to calculate the major covariates required to measure the burden of diseases.

We will calculate HIV/AIDS prevalence under several scenarios derived from existing models of Spectrum software (Estimation and Projection Package). The software will be set under a range of assumptions about the relevant sub-epidemics and four epidemiological parameters which will be used to fit a curve to generate the prevalence trend.<sup>13</sup>

#### Statistical analysis plans

Burden of disease is measured in DALYs. DALYs includes the sum of the Years of Life Lost due to premature death (YLL) and Years Lived with Disability (YLD). YLL will be calculated using age and disease-specific deaths, YLD using estimates of incidence and duration of non-fatal diseases for Iran and disability weights for each disease will be applied from the GBD study.

To access the entire national surveys and address the lack of data or non-informative data (i.e., those with large uncertainty) in some regions, we will use Spatio-temporal and Bayesian multi-level autoregressive models. Moreover, for some of the provinces

which were separated in the specified period of study, the problem of misaligned areal units arise that will settled by both models. In order to verify the model independency of the estimations, we will apply the two mentioned models.

#### Spatio-temporal model

As mentioned before, one of the models to overcome the data scarcity is Spatio-temporal Bayesian hierarchical modeling with conditional autoregressive (CAR) prior for spatial random effects (Spatio-temporal article). As the first assumption in this model, the nearby areas are more linked together than those farther away. This assumption allows model to improve estimations for the areas with incomplete or missing observations through borrowing information from the neighboring areas. Additionally, to join incompatible areal units among various data sources or over the years, spatio-temporal misalignment modeling will be utilized.

#### Bayesian Autoregressive Multilevel model

In this model observations are nested in more than one level, including provinces, sub-regions, regions, and national levels respectively. The hierarchical nature of the model allows higher levels to borrow information to the lower levels depending on the degree of data availability. Also units of each level borrow information to each other in case of data scarcity. The model considers a number of components including nonlinearity associated with age and variation over time, heterogeneity among data sources, linear time trend and covariate effects.

Actually, both models are best handled within a Bayesian framework, and statistical inference is carried out using Markov Chain Monte Carlo (MCMC) simulation. Besides, using regression models provides an opportunity to crosswalk between categorical and continuous variables, for dealing with the problem of different classification of measurement.

## Discussion

The study of the burden of infectious diseases as a sub-component of a comprehensive project named NASBOD has been designed to fill out the information gaps of Iranian health system. The first global burden of diseases (GBD) study was performed in 1990,<sup>14</sup> and recently the results of GBD was updated for 2010.<sup>6</sup> The GBD 1990 study generated comprehensive estimates of mortality and morbidity, and documented the health consequences of 107 diseases by age, sex, and region. A comprehensive update of diseases burden has been done as of the 1990 study and the burden of 291 causes, 20 age groups and for 21 regions in 1990, 2005 and 2010 was performed.<sup>6</sup> The 2010 GBD study determined YLL, YLD, and consequently calculated the DALY as a single measure to quantify the burden of diseases, injuries and risk factors. Generally, burden studies have been conducted in several countries such as USA,<sup>15,16</sup> Australia,<sup>17–19</sup> Netherlands,<sup>20</sup> New Zealand,<sup>21</sup> Mexico,<sup>22,23</sup> Iran,<sup>24</sup> Pakistan,<sup>25</sup> Ghana,<sup>26</sup> Kenya,<sup>27</sup> Nairobi<sup>28</sup> and South Africa,<sup>29</sup> to estimate the burden of infectious diseases.

In a study conducted by Christie and Tobias (1998) in New Zealand, the mortality data was obtained from the Ministry of Health to measure the burden of infectious diseases from 1980 to 1993.<sup>21</sup> They applied the “cause of death” analysis as well as sub group analyses by sex, age, and ethnicity. As a considerable limitation, since they only included mortality data in their study, the researchers were not able to estimate the burden of non-fatal outcomes.

Health surveys, mortality data, vital statistics, national censuses, and published epidemiological studies were used as data sources in Mexico and Australia burden of diseases studies.<sup>17,23</sup> The Mexican researchers assessed all their results based on age; sex and selected regions, while six geographical regions were classified for all analyses based on the socioeconomic status of the population and total mortality numbers.

Naghavi, et al.<sup>24</sup> estimated DALY for diseases in six selected provinces and at national level in 2003 in Iran. After more than a decade, it seems to be essential to conduct a new study with more comprehensive methodology to fulfill the gaps and rectify lack of data regarding the burden of diseases in Iran. The BID study will describe and present the causes, origins, backgrounds and burden of important infectious diseases over a 23-year period. Acquisition of available national data sources and different methodologies provide certain advantages for this study comparing with the previous study in Iran<sup>24</sup> and sub-national studies in other countries.<sup>23,30,31</sup>

Trends of various diseases and pattern of geographical and socioeconomic inequalities at national and provincial levels will be another advantage of the BID study. Likewise, one of the most important strengths of the burden of infectious diseases study can be the consistent assessment of prevalence, incidence, mortality, duration, and severity, as well as a comprehensive list of infectious diseases, which are among the most important health priorities in Iran.

Burden of infectious disease study has also some limitations. First, in case of using the surveillance system reports of the MOH, we will face lack of annual data for our specific categorized years. Besides, it should be considered that acquired data might be influenced by over-reporting or under-reporting. Second, there is limited access to the grey literatures especially for sexually transmitted diseases due to lack of grey sources in Iran. Finally, for

some diseases such as STIs and HIV, stigma inevitably leads to the scarcity of available valid data. However, the research team will apply the statistical models to deal with data scarcity and misalignment problems.

The policy implications are worth emphasizing at both national and sub-national levels. Regional differences in estimated burden would be helpful for highlighting the health concerns, evaluating the prevention interventions, and applying the most effective health policies. Geographical inequalities of diseases can be estimated as background dissimilarity and these results can also be considered as a guideline for resource allocation at sub-national level. Additionally, it seems that trend analysis and consequently the feasibility of further projections are among the most important characteristics of the burden of infectious diseases study.

Results of the BID study might be helpful to find the defects of the existing healthcare system in Iran, monitor the burden and trend of infectious diseases, and manage the relevant costs in the country. Moreover, it should be mentioned that BID study would help the researchers who are going to conduct similar studies not only at national and sub-national levels in Iran, but also around the whole developing world.

## Author's Contribution

**General designing of paper:** Atefeh Noori, Dr. Farshad Farzadfar, Mostafa Shokoohi

**Designing of models:** Dr. Farshad Farzadfar, Atefeh Noori, Alireza Zohouri Zangeneh

**Designing of systematic review:** Atefeh Noori, Dr. Farshad Farzadfar, Mostafa Shokoohi, Shohreh Naderimigham

**Writing primary draft:** Atefeh Noori, Babak Moazen, Mostafa Shokoohi, Shayesteh Hajizadeh

**Manuscript revision:** Dr. Farshad Farzadfar, Dr. Ghobad Moradi, Atefeh Noori, Babak Moazen, Mostafa Shokoohi, Dr. Mohammad Mehdi Gouya

**Approval:** All authors have read and approved the content and the authorship of the final version of the submitted manuscript.

## Acknowledgments

The study is granted by Ministry of Health and Medical Education of Islamic Republic of Iran and Setad-e-Ejraie Farmane Imam. We would like to thank the heads of infectious diseases offices of Iranian Ministry of Health: Dr. Ahmad Raeesi, Dr. Mohsen Zahraee, Dr. Mahmood Soroush, Dr. Mohammad Reza Shirzadi, Dr. Abass Sedaghat, Dr. Hossein Masoomi, and Dr. Mahshid Nashehi. We would also like to express thanks to Dr. Sadaf G. Sepanlou for her helpful comments, Dr. Masoud Moradi for his literally editing of text, and Ms Rosa Haghshenas the staff of Non-communicable Diseases Research Center.

## References

1. World Health Organization, facts: Global health situation and trends In 1955 – 2025.
2. Bryce J, Boschi-Pinto C, Shibuya K, Black RE, WHO estimates of the causes of death in children. *The Lancet*. 2005; **365**: 1147 – 1152.
3. Cohen ML, Changing patterns of infectious disease. *Nature*. 2000; **406**: 762 – 767.
4. Black RE, Morris SS, Bryce J, Where and why are 10 million children

- dying every year? *The Lancet*. 2003; **361**: 2226 – 2234.
5. Mueller-Langer F, Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting research? *Max Planck Institute for Intellectual Property & Competition Law Research Paper*. 2011.
  6. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990 – 2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*. 2013; **380**: 2197 – 2223.
  7. Rethlefsen ML, Livinski AA, Infectious diseases citation patterns: mapping the literature 2008–2010. *Journal of the Medical Library Association: JMLA*. 2013; **101**: 55.
  8. UNAIDS J, Global report: UNAIDS report on the global AIDS epidemic 2010. *UNAIDS Geneva*. 2010.
  9. Khazaei HA, Rezaei N, Bagheri GR, Dankoub MA, Shahryari K, Tahai A, Mahmoudi M, Epidemiology of tuberculosis in the South-eastern Iran. *European journal of epidemiology*. 2005; **20**: 879 – 883.
  10. Ministry of Health (MOH) and Medical Education (ME) of Iran, 2010. Annual Report of Malaria Control Department. CDC, IR Iran, Tehran, pp. 50.
  11. Beheshti S, Rezaian G, Azad F, Faghiri Z, Taheri F. Seroprevalence of brucellosis and risk factors related to high risk occupational groups in kazeroun, South of Iran. *The International Journal of Occupational and Environmental Medicine*. 2010; **1(2)**: 62 – 68.
  12. Wells G, Shea B, O'connell D, Peterson J, Welch V, Losos M, Tugwell P, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In 2000.
  13. Zaba B, Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference group on estimates, modelling and projections. *AIDS*. 2002; **16**: W1 – W14.
  14. Murray CJ, Lopez AD, Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *The Lancet*. 1997; **349**: 1436 – 1442.
  15. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9· 1 million participants. *The Lancet*. 2011; **377**: 557 – 567.
  16. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M, The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. *PLoS medicine*. 2009; **6**: e1000058.
  17. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD, Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. *Medical journal of Australia*. 2008; **188**: 36.
  18. Mathers CD, Vos ET, Stevenson CE, Begg SJ, The burden of disease and injury in Australia. *Bulletin of the World Health Organization*. 2001; **79**: 1076 – 1084.
  19. Vos T, Barker B, Begg S, Stanley L, Lopez AD, Burden of disease and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous health gap. *international Journal of Epidemiology*. 2009; **38**: 470 – 477.
  20. Melse JM, Essink-Bot M-L, Kramers P, Hoeymans N, A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. *American Journal of Public Health*. 2000; **90**: 1241.
  21. Blakely T, Foster R, Wilson N, Costilla R, Tobias M, Sarfati D, O'Dea D, McLeod M, Soeberg M, Hadorn D, Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE 3) Study Protocol. 2012.
  22. Lozano R, Murray C, Frenk J, Bobadilla JL, Burden of disease assessment and health system reform: results of a study in Mexico. *Journal of International Development*. 1995; **7**: 555 – 563.
  23. Stevens G, Dias RH, Thomas KJ, Rivera JA, Carvalho N, Barquera S, Hill K, Ezzati M, Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors. *PLoS medicine*. 2008; **5**: e125.
  24. Naghavi M, Abolhassani F, Pourmalek F, Lakeh MM, Jafari N, Vaseghi S, Hezaveh NM, Kazemeini H, The burden of disease and injury in Iran 2003. *Population health metrics*. 2009; **7**: 9.
  25. Hyder AA, Morrow RH, Applying burden of disease methods in developing countries: a case study from Pakistan. *American Journal of Public Health*. 2000; **90**: 1235.
  26. A quantitative method of assessing the health impact of different diseases in less developed countries. Ghana Health Assessment Project Team. *Int J Epidemiol*. 1981; **10(1)**: 73 – 80.
  27. Snow RW, Gouws E, Omumbo J, Rapuoda B, Craig M, Tanser F, Le Sueur D, Ouma J, Models to predict the intensity of *Plasmodium falciparum* transmission: applications to the burden of disease in Kenya. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1998; **92**: 601 – 606.
  28. Kyobutungi C, Ziraba A, Ezech A, Yé Y, The burden of disease profile of residents of Nairobi's slums: Results from a Demographic Surveillance System. *Population health metrics*. 2008; **6**: 1.
  29. Norman R, Bradshaw D, Schneider M, Joubert J, Groenewald P, Lewin S, Steyn K, Vos T, Laubscher R, Nannan N, A comparative risk assessment for South Africa in 2000: towards promoting health and preventing disease. *South African Medical Journal*. 2007; **97**: 637 – 641.
  30. Christie S, Tobias M, The burden of infectious disease in New Zealand. *Australian and New Zealand journal of public health*. 1998; **22**: 257 – 260.
  31. Zaidi AK, Awasthi S, Janaka deSilva H, Burden of infectious diseases in South Asia. *British Medical Journal*. 2004; **328**: 811 – 815.

## Appendix 1. Search strategies for infectious diseases

<ul style="list-style-type: none"> <li>• Iran [Mesh] OR "I.R.Iran" OR "IR Iran" OR "Islamic Republic of Iran" OR "Iran (Islamic Republic of)" OR "Iran (Islamic Republic)" OR "Iranian" OR "Iranians OR Persia"</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• All related terms of each disease separately</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Incidence OR prevalence</li> </ul>
<p><b>Sexually Transmitted Diseases</b></p> <p>"Disease, Sexually Transmitted" OR "Diseases, Sexually Transmitted" OR "Sexually Transmitted Disease" OR "Sexually Transmitted Diseases" OR STDs OR "Venereal Diseases" OR "Disease, Venereal" OR "Diseases, Venereal" OR "Venereal Disease"</p> <ul style="list-style-type: none"> <li>• <b>HIV</b> "human immunodeficiency virus" OR "Acquired Immunodeficiency Syndrome" OR "AIDS-Related Complex" OR "AIDS-Related Opportunistic Infections" OR "HIV Infections" OR "HIV Seropositivity" OR "AIDS-Related Complex" OR "HIV Seroprevalence" OR "HIV-1" OR "HIV-2"</li> <li>• <b>Chancroid</b> Chancroid*</li> <li>• <b>Chlamydia Infections</b> "Infections, Chlamydia" OR "Chlamydia Infection" OR "Chlamydia Infections" OR "Infection, Chlamydia"</li> <li>• <b>Gonorrhoea</b> Gonorrhoea*</li> <li>• <b>Granuloma Inguinale</b> "Granuloma Venereum" OR Donovanosis OR "Granuloma Inguinale"</li> <li>• <b>Syphilis</b> "Great Pox" OR "Pox, Great" OR syphilis</li> <li>• <b>Condylomata Acuminata</b> "Venereal Warts" OR "Condylomata Acuminata" OR "Venereal Wart" OR "Wart, Venereal" OR "Warts, Venereal" OR "Genital Warts" OR "Genital Wart" OR "Wart, Genital" OR "Warts, Genital"</li> <li>• <b>Herpes Genitalis</b> "Genital Herpes" OR "Herpes, Genital" OR "Herpes Genitalis" OR "Herpes Simplex Virus Genital Infection" OR "Herpes Simplex, Genital" OR "Genital Herpes Simplex"</li> <li>• <b>Urogenital Diseases</b> "Urogenital Disease" OR "Urogenital Diseases" OR "Genitourinary Diseases" OR "Genitourinary Disease"</li> <li>• <b>Genital Diseases</b> "Gynecologic Diseases" OR "Diseases, Gynecologic" OR "Gynecologic Disease" OR "Genital Diseases" OR "Diseases, Genital" OR "Genital Disease"</li> <li>• <b>Lymphogranuloma Venereum</b> "Lymphogranuloma Inguinale" OR "Lymphogranuloma Venereum"</li> <li>• <b>Chancere</b> Chancere*</li> <li>• <b>Trichomonas</b> Trichomona*</li> </ul>
<p><b>Zoonosis</b></p>

- **Malaria**

Remittent Fever OR Fever, Remittent OR Paludism OR Plasmodium Infections OR Infections, Plasmodium OR Infection, Plasmodium OR Plasmodium Infection OR Marsh Fever OR Fever, Marsh OR Malaria, Avian OR Avian Malaria OR Avian Malaria OR Plasmodium falciparum Malaria OR Malaria, Plasmodium falciparum OR Vivax Malaria Plasmodium OR vivax Malaria Malaria, OR Plasmodium vivax

- **Brucellosis**

Brucellosis OR Gibraltar Fever OR Fever, Gibraltar OR Rock Fever OR Fever, Rock OR Fevers, Rock OR Rock Fevers OR Undulant Fever OR Fever, Undulant OR Fevers, Undulant OR Undulant Fevers OR Cyprus Fever OR Cyprus Fevers OR Fever, Cyprus OR Fevers, Cyprus OR Malta Fever OR Fever, Malta OR Brucellosis, Pulmonary OR Brucellosis, Pulmonary OR Pulmonary Brucellosis OR Pulmonary Brucellosis

- **Brucellosis, Bovine**

Bovine Brucellosis OR Bovine Brucellosis OR Brucellosis, Bovine OR Bang's Disease OR Bangs Disease OR Disease, Bang's OR Bang Disease

- **Leishmaniasis**

Cutaneous Leishmaniasis OR Cutaneous Leishmaniasis OR Leishmaniasis, Cutaneous OR Oriental Sore OR Leishmaniasis, Cutaneous OR Visceral Leishmaniasis OR Kala-Azar OR Kala Azar OR Black Fever Fever, Black

- **Hidatid cystics**

Echinococcoses, Hepatic OR Hepatic Echinococcoses OR Echinococcosis, Hepatic OR Parovarian Cyst OR Hepatic Echinococcosis OR Echinococcosis, Hepatic Alveolar OR Alveolar Echinococcoses, Hepatic OR Alveolar Echinococcosis, Hepatic OR Echinococcoses, Hepatic Alveolar OR Hepatic Alveolar Echinococcoses OR Hepatic Alveolar Echinococcosis OR Hydatidosis, Hepatic OR Hepatic Hydatidosis OR Hepatic Hydatidosis OR Hydatidosis, Hepatic OR Alveolar Echinococcosis, Hepatic OR Echinococcosis, Hepatic Alveolar OR Hepatic Alveolar Echinococcosis OR Hydatid Cyst, Hepatic OR Cyst, Hepatic Hydatid OR Cysts, Hepatic Hydatid OR Hepatic Hydatid Cyst OR Hepatic Hydatid Cysts OR Hydatid Cysts, Hepatic OR Hydatid Cyst of Morgagni OR Morgagni Hydatid Cyst OR Morgagni Hydatid Cysts OR Echinococcoses OR Hydatid Cyst OR Hydatidosis OR Hydatidosis OR Cysts, Hydatid OR Cyst, Hydatid OR Hydatid Cysts OR Echinococcosis

### Vaccine preventable diseases

- **Measles**

Rubellas OR Three Day Measles OR Measle, OR Three Day Measles, OR Three Day OR Three Day Measle OR German Measles Syndrome OR Congenital Rubella OR Rubella Syndrome, Congenital OR Congenital Rubella Syndromes

- **Rubella**

Rubella virus OR Rubellas OR Three Day Measles OR Measle, Three Day OR Measles, Three Day OR Three Day Measle OR Measles, German OR German Measles

- **Tetanus**

Tetanus Toxoid

- **Diphtheria**

Diphtherias OR Bacterial Infections and Mycoses

Gram-Positive Bacterial Infections

Gram Positive Bacterial Infections OR Infections, Gram-Positive Bacterial OR Bacterial Infection, Gram-Positive OR Gram-Positive Bacterial Infection OR Infection, Gram-Positive Bacterial OR Infections, Gram Positive Bacterial OR Bacterial Infections, Gram-Positive OR Bacterial Infections, Gram Positive

- **Bordetella pertussis**

Hemophilus pertussis OR Haemophilus pertussis OR Bordetella OR Bordetella avium OR Bordetella bronchiseptica OR Bordetella parapertussis

- **Poliomyelitis**

Epidemic Acute Poliomyelitis OR Acute Poliomyelitis, Epidemic OR Poliomyelitis, Epidemic Acute OR Poliomyelitis, Acute OR Acute Poliomyelitis OR Polio OR Polios OR Poliomyelitis, Preparalytic OR Poliomyelitis, Preparalytic OR Preparalytic Poliomyelitis OR Poliomyelitis, Nonpoliovirus OR Nonpoliovirus Poliomyelitis OR Encephalitis, Polio OR Polio Encephalitis OR Infantile Paralysis OR Paralysis, Infantile OR Poliomyelitis, Bulbar OR Bulbar Poliomyelitis OR Poliomyelitis, Medullary Involvement OR Medullary Involvement Poliomyelitis OR Bulbar Polio OR Polio, Bulbar OR Postpoliomyelitis Syndrome OR Post-Polio Syndrome OR Post-Polio Syndromes OR Post-Poliomyelitis Syndrome OR Post Poliomyelitis Syndrome

### Respiratory Tract Infections

Infection, Respiratory Tract OR Respiratory Tract Infection OR Respiratory Infections OR Infections, Respiratory OR Infections, Respiratory Tract OR Upper Respiratory Tract Infections

Infections, Upper Respiratory Tract OR Upper Respiratory Infections OR Infections, Upper Respiratory OR Respiratory Infection, Upper